Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
2473 | 2164 | 42.5 | 91% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CD40 | Author keyword | 191 | 38% | 19% | 405 |
2 | CD40 LIGAND | Author keyword | 165 | 52% | 10% | 222 |
3 | CD40L | Author keyword | 82 | 42% | 7% | 148 |
4 | CD154 | Author keyword | 44 | 42% | 4% | 80 |
5 | X LINKED HYPER IGM SYNDROME | Author keyword | 41 | 87% | 1% | 20 |
6 | HYPER IGM SYNDROME | Author keyword | 29 | 53% | 2% | 38 |
7 | SOLUBLE CD40 LIGAND | Author keyword | 26 | 50% | 2% | 38 |
8 | SCD40L | Author keyword | 16 | 39% | 2% | 33 |
9 | CD40 LIGAND DEFICIENCY | Author keyword | 15 | 77% | 0% | 10 |
10 | GP39 | Author keyword | 10 | 61% | 1% | 11 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CD40 | 191 | 38% | 19% | 405 | Search CD40 | Search CD40 |
2 | CD40 LIGAND | 165 | 52% | 10% | 222 | Search CD40+LIGAND | Search CD40+LIGAND |
3 | CD40L | 82 | 42% | 7% | 148 | Search CD40L | Search CD40L |
4 | CD154 | 44 | 42% | 4% | 80 | Search CD154 | Search CD154 |
5 | X LINKED HYPER IGM SYNDROME | 41 | 87% | 1% | 20 | Search X+LINKED+HYPER+IGM+SYNDROME | Search X+LINKED+HYPER+IGM+SYNDROME |
6 | HYPER IGM SYNDROME | 29 | 53% | 2% | 38 | Search HYPER+IGM+SYNDROME | Search HYPER+IGM+SYNDROME |
7 | SOLUBLE CD40 LIGAND | 26 | 50% | 2% | 38 | Search SOLUBLE+CD40+LIGAND | Search SOLUBLE+CD40+LIGAND |
8 | SCD40L | 16 | 39% | 2% | 33 | Search SCD40L | Search SCD40L |
9 | CD40 LIGAND DEFICIENCY | 15 | 77% | 0% | 10 | Search CD40+LIGAND+DEFICIENCY | Search CD40+LIGAND+DEFICIENCY |
10 | GP39 | 10 | 61% | 1% | 11 | Search GP39 | Search GP39 |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | GP39 | 127 | 79% | 4% | 82 |
2 | X LINKED IMMUNODEFICIENCY | 121 | 51% | 8% | 172 |
3 | DEFECTIVE EXPRESSION | 108 | 62% | 5% | 111 |
4 | FUNCTIONAL CD40 | 96 | 87% | 2% | 47 |
5 | CD40 CD40 LIGAND | 93 | 57% | 5% | 112 |
6 | HYPER IGM SYNDROME | 89 | 35% | 10% | 206 |
7 | ELEVATED IGM | 72 | 100% | 1% | 23 |
8 | CD40 LIGAND | 65 | 17% | 16% | 356 |
9 | CD154 | 59 | 51% | 4% | 83 |
10 | VIVO CD40 GP39 INTERACTIONS | 43 | 60% | 2% | 47 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
CD40-CD40 ligand | 2000 | 776 | 128 | 63% |
The CD40-CD40L system in cardiovascular disease | 2011 | 39 | 83 | 88% |
Molecular mechanism and function of CD40/CD40L engagement in the immune system | 2009 | 227 | 217 | 33% |
The CD40/CD154 receptor/ligand dyad | 2001 | 430 | 517 | 56% |
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials | 2014 | 13 | 63 | 49% |
CD40 and CD154 in cell-mediated immunity | 1998 | 1038 | 102 | 59% |
CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease | 2008 | 60 | 93 | 66% |
CD40 Ligand: A neo-inflammatory molecule in vascular diseases | 2012 | 17 | 94 | 69% |
CD40 signaling and plaque instability | 2001 | 362 | 136 | 48% |
CD40 and autoimmunity: The dark side of a great activator | 2009 | 83 | 123 | 53% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | UW COMPREHENS CANC | 4 | 75% | 0.1% | 3 |
2 | WEBB WARING | 4 | 31% | 0.5% | 11 |
3 | IMMUNOL CELLULAIRE MOL | 4 | 41% | 0.3% | 7 |
4 | MED 0679 | 3 | 57% | 0.2% | 4 |
5 | CLIN SCI K4 413 | 3 | 100% | 0.1% | 3 |
6 | MED CLIN IMMUNOL JIANGSU PROV | 3 | 37% | 0.3% | 7 |
7 | DIS PATHOGENESIS PROGRAM | 2 | 67% | 0.1% | 2 |
8 | MEDVASC MED ATHEROSCLEROSIS UNIT | 2 | 67% | 0.1% | 2 |
9 | PANAGIOTIS AGLAIA KYRIAKOU PEDIAT HOSP | 2 | 67% | 0.1% | 2 |
10 | CELL GENE THER Y PROGRAM | 2 | 33% | 0.2% | 5 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000129860 | TAK1//TRAF4//TRAF5 |
2 | 0.0000072995 | MEMORY B CELL//GERMINAL CENTER//B CELL MIGRATION |
3 | 0.0000066213 | COSTIMULATION BLOCKADE//EMORY TRANSPLANT//MIXED CHIMERISM |
4 | 0.0000064837 | PLATELET PROTEOME//EFS AUVERGNE LOIRE//SECT CARDIOIMMUNOL |
5 | 0.0000064720 | 4 1BB//OX40//CD137 |
6 | 0.0000064077 | TL 2 RESPONSE//ADCC REACTION//ANTI IG DEXTRAN |
7 | 0.0000059385 | CD28//CD80//B7 |
8 | 0.0000048858 | REGULATORY B CELLS//CD40 ACTIVATED B CELLS//REGULATORY B CELL |
9 | 0.0000046891 | U396//HU1D10//UNITE 396 |
10 | 0.0000044253 | SOMATIC HYPERMUTATION//CLASS SWITCH RECOMBINATION//ACTIVATION INDUCED CYTIDINE DEAMINASE |